Table 1. Full inclusion and exclusion criteria.

Inclusion criteria	Exclusion criteria
Age 18 years or older.	History of idiopathic seizure disorder, psychosis or schizophrenia.
A previous histopathologically verified diagnosis of glioblastoma/ gliosarcoma (later referred to as only glioblastoma) now presenting with a first-time progression/recurrence documented by MRI.	Uncontrolled hypertension (i.e. systolic BP > 180 mmHg) and a diagnosis of congestive heart failure
Planned treatment of recurrence with chemotherapeutic alkylating agents	Received radiotherapy within the 3 months before the diagnosis of tumor progression to reduce risk of misdiagnosis due to pseudoprogression.
Karnofsky performance status of 60 – 100 22.	Addiction to alcohol or drugs.
At inclusion not receiving another experimental treatment, including compassionate use programs, for glioblastoma	Pregnant and/or breastfeeding and women of childbearing potential who do not have a negative pregnancy test taken no longer than 14 days prior to randomization.
Able to take oral medications.	History of liver disease.
No known allergy to DSF or copper.	History of Wilson's disease.
Absolute neutrophil count ≥ 1,500/mcL and platelets ≥ 100,000/mcL	History of hemochromatosis.
Willingness to refrain from ingestion of alcoholic beverages while in the study is a criterion to be randomized. However, once randomized alcohol abstinence only affects the group treated with DSF	Nickel hypersensitivity 8
	Need for metronidazole, warfarin and/or theophylline medication since their metabolism may be influenced by DSF.
	Patients who are taking medications metabolized by cytochrome P450 2E1
	Unfit for participation for any other reason judged by the including physician